Unpacking Royalty Pharma

A dire market has seen numerous biotechs feeling the pinch, and because Royalty Pharma can offer such companies instant cash its business has flourished. Poor market conditions surely lie behind an uptick in royalty financings, such as Royalty’s recent deals for Gavreto and Trelegy Ellipta, and Omers Capital Markets picking up Ultragenyx’s Crysvita last week.